Ingredient Repository · Ingredient

🌿
Ingredient

Lactobacillus rhamnosus

The world's most documented probiotic strain, supporting antibiotic recovery, vaginal health, and immune resilience.

What it is

Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) is the single most extensively researched probiotic bacterium in medical science. Cultured via large-scale bio-fermentation and freeze-drying, L. rhamnosus features pili structures equipped with mucus-binding proteins that facilitate firm intestinal attachment. In Velobiotics products, L. rhamnosus is encased in patented MEP microencapsulation, insulating live bacterial cells from stomach acid and bile salts to maximize functional mucosal colonization.

Also known as: L. rhamnosus, Lacticaseibacillus rhamnosus

What it does

  • Prevents and reduces duration of antibiotic-associated diarrhea.
  • Supports urogenital health and protects against recurrent vaginal dysbiosis.
  • Promotes skin health and reduces eczema incidence in infants.
  • Reinforces gut barrier tight junctions against pathogen translocation.

Amplified by probiotics

Lactobacillus rhamnosus functions as a cornerstone strain in multi-species probiotic combinations. Its specialized SpaCBA pili allow it to adhere tightly to intestinal mucus, forming a physical barrier that prevents pathogen colonization and provides an anchor for companion strains like Bifidobacterium lactis. Through robust lactic acid secretion, L. rhamnosus lowers intestinal pH, enhancing the solubility of dietary minerals like zinc and calcium. This acidic milieu also stimulates indigenous butyrate producers via organic acid cross-feeding. Furthermore, L. rhamnosus releases p40 and p75 soluble proteins that prevent cytokine-induced apoptosis of epithelial cells. Protected by Velobiotics MEP microencapsulation during stomach passage, L. rhamnosus reliably stabilizes gut barrier integrity and immune signaling.

Typical dose

1–20 billion CFU/day

The evidence

Evidence: strong

Extensive systematic reviews and meta-analyses confirm that Lactobacillus rhamnosus effectively prevents antibiotic-associated diarrhea, supports vaginal microbiome balance, and reduces childhood atopic dermatitis risk. Clinical trials validate its power in reinforcing gut barrier function. (Huang Y 2026, Front Cell Infect Microbiol) (García G 2026, Front Cell Infect Microbiol) (Altunsaray A 2026, Clin Nutr)

  1. Huang Y, et al. Effect of perioperative multistrain probiotics on the CT callus volume fraction at 12 weeks after surgery for closed tibial shaft fracture: a single-center randomized controlled study. Front Cell Infect Microbiol. 2026;16:1778557 PubMed ↗
  2. García G, et al. Del immune V and microbiome restructuring in colorectal cancer surgery: a randomized double blind placebo controlled trial. Front Cell Infect Microbiol. 2026;16:1853373 PubMed ↗
  3. Altunsaray A, et al. Effects of early postoperative synbiotic supplementation on gastrointestinal outcomes after sleeve gastrectomy: A randomized controlled trial. Clin Nutr. 2026;63:106717 PubMed ↗

Safety & who should check first

Lactobacillus rhamnosus has an unblemished safety record in hundreds of human clinical trials involving premature infants, adults, and elderly populations. It is standardly recommended and well tolerated.